<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Avalglucosidase alfa: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Avalglucosidase alfa: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Avalglucosidase alfa: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="132354" href="/d/html/132354.html" rel="external">see "Avalglucosidase alfa: Drug information"</a> and <a class="drug drug_patient" data-topicid="132382" href="/d/html/132382.html" rel="external">see "Avalglucosidase alfa: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F56044896"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions, including anaphylaxis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Patients treated with avalglucosidase alfa have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available during avalglucosidase alfa administration. If a severe hypersensitivity reaction (eg, anaphylaxis) occurs, discontinue avalglucosidase alfa immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reactions, a desensitization procedure to avalglucosidase alfa may be considered.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infusion-associated reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Patients treated with avalglucosidase alfa have experienced severe infusion-associated reactions (IARs). If severe IARs occur, consider immediate discontinuation of avalglucosidase alfa, initiation of appropriate medical treatment, and the benefits and risks of readministering avalglucosidase alfa following severe IARs. Patients with an acute underlying illness at the time of avalglucosidase alfa infusion may be at greater risk for IARs. Patients with advanced Pompe disease may have compromised cardiac and respiratory function, which may predispose them to a higher risk of severe complications from IARs.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk of acute cardiorespiratory failure in susceptible patients:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Patients susceptible to fluid volume overload, or those with acute underlying respiratory illness or compromised cardiac or respiratory function for whom fluid restriction is indicated may be at risk of serious exacerbation of their cardiac or respiratory status during avalglucosidase alfa infusion. More frequent monitoring of vitals should be performed during avalglucosidase alfa infusion in such patients.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56117897"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nexviazyme</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56674073"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Nexviazyme</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F56048147"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Enzyme</span></li></ul></div>
<div class="block dop drugH1Div" id="F56136559"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Pretreatment with antihistamines, antipyretics, and/or corticosteroids can be considered to reduce risk of infusion reactions. Calculate avalglucosidase alfa dose based on actual body weight.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eddc0866-07d9-48be-98d3-e27324019fe1">Pompe disease, late onset</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pompe disease, late onset:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;30 kg: IV: 40 mg/kg/dose every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">≥30 kg: IV: 20 mg/kg/dose every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling</i>: Infants &gt;6 months, Children, and Adolescents: IV: 20 mg/kg/dose every 2 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Hypersensitivity:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Mild or moderate: </i>Decrease infusion rate or temporarily discontinue avalglucosidase alfa. If symptoms persist despite temporarily stopping the infusion, wait ≥30 minutes for symptoms to resolve (before deciding to stop infusion for the day). If symptoms subside, may resume the infusion at one-half of the infusion rate at which reaction occurred for 30 minutes, then increase the infusion rate by 50% for 15 to 30 minutes. If symptoms do not recur, increase the infusion rate to the rate at which the reaction occurred and continue to increase rate in a stepwise manner.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Severe hypersensitivity or anaphylaxis:</i> Discontinue avalglucosidase alfa immediately and begin appropriate medical management. Some patients have been rechallenged using decreased infusion rates and lower than approved doses. In patients with a severe hypersensitivity reaction, may consider a desensitization procedure. If tolerated, the infusion rate and dose may be increased to reach the usual recommended dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Infusion-associated reaction:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Mild or moderate:</i> Consider temporarily stopping avalglucosidase alfa infusion or decreasing the infusion rate, and begin appropriate medical management. If symptoms persist despite temporarily stopping the infusion, wait at least 30 minutes for symptoms to resolve (before deciding to stop infusion for the day). If symptoms subside, may resume the infusion at one-half of the infusion rate at which reaction occurred for 30 minutes, then increase the infusion rate by 50% for 15 to 30 minutes. If symptoms do not recur, increase the infusion rate to the rate at which the reaction occurred and continue to increase rate in a stepwise manner.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Severe:</i> Discontinue avalglucosidase alfa immediately and begin appropriate medical management. Some patients have been rechallenged using decreased infusion rates and lower than approved doses. If tolerated, the dose may be increased to reach the usual recommended dose.</p></div>
<div class="block dorp drugH1Div" id="F56136560"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F56136561"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F56152407"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="132354" href="/d/html/132354.html" rel="external">see "Avalglucosidase alfa: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Consider pretreatment with antihistamines, antipyretics, and/or corticosteroids to reduce the risk of infusion-associated reactions.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eddc0866-07d9-48be-98d3-e27324019fe1">Pompe disease, late onset</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pompe disease, late onset: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Actual body weight &lt;30 kg: <b>IV:</b> 40 mg/kg every 2 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">Actual body weight ≥30 kg: <b>IV:</b> 20 mg/kg every 2 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose: </i>If ≥1 dose is missed, restart treatment as soon as possible while maintaining the 2-week interval between infusions thereafter.</p></div>
<div class="block dora drugH1Div" id="F56152409"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F56152410"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F56541347"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients treated with avalglucosidase alfa have commonly experienced <b>hypersensitivity reaction</b>, including life-threatening <b>severe hypersensitivity reaction</b> and <b>anaphylaxis.</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immediate hypersensitivity reactions are considered IgE mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher anti-avalglucosidase alfa-ngpt antibody titers (antidrug antibodies [ADA])</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher infusion rates</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infusion-related reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infusion-related reactions</b>, including chest discomfort, <b>diarrhea</b>, <b>dizziness</b>, dysphagia, edema, <b>erythema of skin</b>, <b>headache</b>, <b>hypertension</b>, <b>hypotension</b>, hypoxia, flu-like symptoms, <b>nausea</b>, respiratory distress, and tongue edema have been reported with avalglucosidase alfa; reactions can be severe.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic. <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; occurred at the time of infusion and/or within a few hours after completion of the infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Acute underlying illness at the time of avalglucosidase alfa infusion</p>
<p style="text-indent:-2em;margin-left:6em;">• Advanced Pompe disease with compromised cardiac and respiratory function</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher infusion rates</p>
<p style="text-indent:-2em;margin-left:6em;">• High anti-avalglucosidase alfa-ngpt antibody titers (antidrug antibodies [ADA]) (peak titer ≥12,800)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F56053022"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adolescents and adults from late-onset Pompe disease trials and may include infantile-onset Pompe disease data (off-label indication) in children.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis [2%] and severe hypersensitivity reaction [4%]), infusion-related reaction (25% to 34%; severe [4%])<span class="lexi-table-link-container"> (<a aria-label="Infusion-Related Reaction table link" class="lexi-table-link" data-table-id="lexi-content-infusion-related-reaction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-infusion-related-reaction')">table 1</a>)</span><span class="table-link" style="display:none;">Infusion-Related Reaction</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Infusion-Related Reaction" frame="border" id="lexi-content-infusion-related-reaction" rules="all">
<caption style="text-align:center;">
<b>Avalglucosidase Alfa: Adverse Reaction: Infusion-Related Reaction</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Avalglucosidase Alfa)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Alglucosidase Alfa)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Avalglucosidase Alfa)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Alglucosidase Alfa)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">34%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">33%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adolescents and adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 mg/kg given every other week for 49 weeks</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">51</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">49</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (including neutralizing antibodies)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue, headache</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing, hypertension, hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, dizziness, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Respiratory: Respiratory distress</p></div>
<div class="block coi drugH1Div" id="F56044900"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Life-threatening hypersensitivity to avalglucosidase alfa or any component of the formulation when rechallenge was unsuccessful.</p></div>
<div class="block foc drugH1Div" id="F56117898"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nexviazyme: Avalglucosidase alfa-ngpt 100 mg (1 ea) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F56117896"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56136952"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Nexviazyme Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $2,225.60</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56674074"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nexviazyme: Avalglucosidase alfa-ngpt 100 mg (1 ea) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F56136571"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV infusion: Infuse through a separate line via an in-line, low-protein-binding, 0.2 micron filter. Administer the infusion incrementally according to patient weight and as determined by the patient's response and comfort. Infusion time varies (~4 to 7 hours), but infusion must be completed within 9 hours of dilution or if refrigerated, within 9 hours after removal from refrigerator. Infusion rate calculations based on patient actual body weight.</p>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Patient weight &lt;30 kg (40 mg/kg/dose):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial infusion:</i> Initiate infusion at 1 mg/kg/hour. If tolerated and no signs of infusion-related reactions are seen, gradually increase the infusion rate every 30 minutes as follows: 3 mg/kg/hour, 5 mg/kg/hour, then 7 mg/kg/hour. Maintain infusion rate at 7 mg/kg/hour until the infusion is complete (~7 hours). After infusion is complete, flush line with D5W.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Subsequent infusions:</i></p>
<p style="text-indent:-2em;margin-left:8em;">7-hour infusion (4-step): May administer following same as initial infusion above (~7 hours).</p>
<p style="text-indent:-2em;margin-left:8em;">5-hour infusion (5-step): Initiate infusion at 1 mg/kg/hour. If tolerated and no signs of infusion-related reactions are seen, gradually increase the infusion rate every 30 minutes as follows: 3 mg/kg/hour, 6 mg/kg/hour, 8 mg/kg/hour, then 10 mg/kg/hour. Maintain the infusion rate at 10 mg/kg/hour until the infusion is complete (~5 hours). After infusion is complete, flush line with D5W.</p>
<p style="text-indent:-2em;margin-left:4em;">Patient weight ≥30 kg (20 mg/kg/dose):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial infusion and subsequent infusions:</i> Initiate infusion at 1 mg/kg/hour. If tolerated and no signs of infusion-related reactions are observed, gradually increase the infusion rate every 30 minutes as follows: 3 mg/kg/hour, 5 mg/kg/hour, then 7 mg/kg/hour. Maintain infusion rate at 7 mg/kg/hour until the infusion is complete (~4 to 5 hours). After infusion is complete, flush line with D5W.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling</i>: Infants &gt;6 months, Children, and Adolescents (20 mg/kg/dose regardless of weight): <i> Initial infusion and subsequent infusions</i>: Initiate infusion at 1 mg/kg/hour. If tolerated and no signs of infusion-related reactions are seen, gradually increase the infusion rate every 30 minutes as follows: 3 mg/kg/hour, 5 mg/kg/hour, then 7 mg/kg/hour. Maintain infusion rate at 7 mg/kg/hour until the infusion is complete. After infusion is complete, flush line with D5W (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nexviazyme.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nexviazyme.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity and/or infusion-related reaction modifications:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to moderate hypersensitivity or moderate infusion-related reactions: </i>Decrease infusion rate or temporarily hold infusion. If symptoms persist despite temporarily holding the infusion, wait ≥30 minutes for symptoms to resolve before deciding to stop infusion for the day. If symptoms subside, may re-initiate infusion at 50% of rate at which reaction occurred for 30 minutes; if patient remains without symptoms, increase infusion rate by 50% for 15 to 30 minutes; if symptoms do not recur, increase to rate at which reaction occurred and consider continuing to increase rate in a stepwise manner.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe hypersensitivity or infusion-related reaction:</i> Discontinue treatment and initiate appropriate medical treatment.</p></div>
<div class="block adm drugH1Div" id="F56152412"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> If diluted solution was refrigerated, allow solution to reach room temperature (30 minutes) prior to infusion. Infuse through a separate line via an inline, low-protein-binding, 0.2-micron filter.</p>
<p style="text-indent:-2em;margin-left:4em;">Discontinue immediately and initiate appropriate medical treatment for severe hypersensitivity (including anaphylaxis) or severe infusion reaction; decrease infusion rate or temporarily hold avalglucosidase alfa for mild to moderate hypersensitivity or infusion reaction.</p>
<p style="text-indent:-2em;margin-left:4em;">Diluted solution for infusion must be used within 9 hours after preparation or within 9 hours after removal from refrigerator (if stored); discard any unused portion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Actual body weight &lt;30 kg (40 mg/kg/dose):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial infusion</i>: Initiate IV infusion at 1 mg/kg/hour. If tolerated, gradually increase the infusion rate every 30 minutes as follows: 3 mg/kg/hour, then 5 mg/kg/hour, then 7 mg/kg/hour. Then, maintain infusion rate at 7 mg/kg/hour until the infusion is complete (total IV infusion duration: ~7 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Subsequent infusions: </i>Initiate IV infusion at 1 mg/kg/hour. If tolerated, gradually increase infusion rate as described under the initial infusion protocol above (total IV infusion duration: ~7 hours); alternatively, may gradually increase the infusion rate every 30 minutes as follows: 3 mg/kg/hour, then 6 mg/kg/hour, then 8 mg/kg/hour, then 10 mg/kg/hour. Then, maintain the infusion rate at 10 mg/kg/hour until the infusion is complete (total IV infusion duration: ~5 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Actual body weight ≥30 kg (20 mg/kg/dose):</b> Initiate IV infusion at 1 mg/kg/hour. If tolerated, gradually increase the infusion rate every 30 minutes as follows: 3 mg/kg/hour, then 5 mg/kg/hour, then 7 mg/kg/hour. Then, maintain infusion rate at 7 mg/kg/hour until the infusion is complete (total IV infusion duration: ~4 to 5 hours).</p></div>
<div class="block sts drugH1Div" id="F56152399"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 2°C to 8°C (36°F to 46°F). Following reconstitution and/or dilution for infusion, may store for up to 24 hours at 2°C to 8°C (36°F to 46°F); do not freeze. Diluted solution for infusion must be used within 9 hours after preparation or within 9 hours after removal from refrigerator (if stored).</p></div>
<div class="block usep drugH1Div" id="F56048145"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) (FDA approved in ages ≥1 year and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Treatment of late-onset Pompe disease in patients &gt;6 months of age.</p></div>
<div class="block mst drugH1Div" id="F56152395"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Avalglucosidase alfa may be confused with agalsidase alfa, agalsidase beta, alglucosidase alfa, andexanet alfa, or asfotase alfa.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F56099861"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F56099858"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F56152396"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">In a phase I safety trial, patients who could become pregnant were required to use effective contraception.</p></div>
<div class="block pri drugH1Div" id="F56152397"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to the treatment of Pompe disease during pregnancy is limited; when use of enzyme replacement therapy is noted, available reports use alglucosidase alfa (refer to the Alglucosidase Alfa monograph for additional information).</p>
<p style="text-indent:0em;margin-top:2em;">Adverse events, such as worsening muscle weakness or decreased respiratory function, may be exacerbated by pregnancy and/or Pompe disease (Karabul 2014). The continuation of enzyme replacement therapy during pregnancy may be considered (van der Ploeg 2017).</p>
<p style="text-indent:0em;margin-top:2em;">A registry has been established for patients diagnosed with Pompe disease; pregnant patients are encouraged to enroll in the registry (1-800-745-4447, extension 15500).</p></div>
<div class="block mopp drugH1Div" id="F56136575"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs during (prior to each infusion rate increase) and following infusion; more frequent monitoring suggested for patients at risk for fluid overload.</p></div>
<div class="block pha drugH1Div" id="F56152401"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Avalglucosidase alfa is an exogenous source of the enzyme acid alpha-glucosidase (GAA), which is required for glycogen cleavage. Due to an inherited GAA deficiency or absence, glycogen accumulates in the tissues of patients with Pompe disease. Mannose-6-phosphate (M6P) on avalglucosidase alfa mediates binding to M6P receptors on the cell surface with high affinity. After binding, it is internalized and transported to lysosomes where it is activated for increased enzymatic glycogen cleavage.</p></div>
<div class="block phk drugH1Div" id="F56152402"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 3.4 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Expected to be metabolized into small peptides and amino acids via catabolic pathways.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 1.6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: 0.9 L/hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58216563"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Nexviazyme</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Nexviadyme</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Nexviazyme</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Nexviadyme</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Nexviadyme</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Nexviadyme</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Nexviadyme</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Nexviazyme</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Nexviazyme</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Nexviazyme</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avalglucosidase-alfa-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24726296">
<a name="24726296"></a>Karabul N, Berndt J, Kornblum C, et al. Pregnancy and delivery in women with Pompe disease. <i>Mol Genet Metab</i>. 2014;112(2):148-153. doi:10.1016/j.ymgme.2014.03.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avalglucosidase-alfa-pediatric-drug-information/abstract-text/24726296/pubmed" id="24726296" target="_blank">24726296</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nexviazyme (avalglucosidase alfa) [prescribing information]. Cambridge, MA: Genzyme Corporation; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nexviazyme.1">
<a name="Nexviazyme.1"></a>Nexviazyme (avalglucosidase alfa) [product monograph]. Toronto, Ontario, Canada: Sanofi-Aventis Canada Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30770310">
<a name="30770310"></a>Pena LDM, Barohn RJ, Byrne BJ, et al; NEO1 Investigator Group. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase 1, open-label, multicenter, multinational, ascending dose study. <i>Neuromuscul Disord</i>. 2019;29(3):167-186. doi:10.1016/j.nmd.2018.12.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avalglucosidase-alfa-pediatric-drug-information/abstract-text/30770310/pubmed" id="30770310" target="_blank">30770310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28477382">
<a name="28477382"></a>van der Ploeg AT, Kruijshaar ME, Toscano A, et al; European Pompe Consortium. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. <i>Eur J Neurol</i>. 2017;24(6):768-e31. doi:10.1111/ene.13285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/avalglucosidase-alfa-pediatric-drug-information/abstract-text/28477382/pubmed" id="28477382" target="_blank">28477382</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 132355 Version 37.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
